



FP7 Collaborative Project DDRresponse

International Symposium on “The promise of PARP inhibitors for Personalized Cancer Treatment”

Heineken Experience, Amsterdam, NL
26-28 January, 2015



Day 1, Monday 26 January

Time	Presenter + Title
12.00 – 13.30	Lunch
13:30 – 13:45	Opening by Prof. Jan Hoeijmakers
13.45 – 14.30	Prof. Steve Jackson, University of Cambridge, UK <i>DNA repair inhibition and synthetic lethality: from concept to clinical benefit</i>
14.30 – 15.15	Prof. Roland Kanaar, Erasmus MC, Rotterdam, the Netherlands <i>Induced synthetic lethality to extend PARP inhibition therapy</i>
15.15 – 16.00	Tea/coffee
	PARP inhibitors; past, present and future
16.00 – 16.25	Prof. Jan Hoeijmakers, Erasmus MC, Rotterdam, the Netherlands <i>DDRresponse from mechanistic understanding to cancer treatment</i>
16.25 – 16.50	Dr. Mark O'Connor, AstraZeneca, UK <i>The development of the PARP inhibitor Lynparza</i>
16.50 – 17.00	Discussion
17.00 – 20.30	Drinks followed by walking dinner

Day 2, Tuesday 27 January

Time	Presenter + Title
	Session 1: Improving therapy response
9.00 – 9.30	Prof. Christian Reinhardt, University Hospital Cologne, Germany <i>Targeting cell cycle checkpoints for personalized cancer therapy</i>
9.30 – 10.00	Dr. Jean-Philippe Gagné, Centre de recherche du CHU de Québec, Canada <i>The emergence of mass spectrometry-based technologies for the identification of covalently poly(ADP-ribosylated) proteins</i>
10.00 – 10.30	Dr. Mark O'Connor, AstraZeneca, UK <i>Expanding the potential for Lynparza beyond monotherapy in BRCAm ovarian cancer</i>
10.30 – 11.00	Coffee
	Session 2: Normal tissue toxicity and therapy resistance
11.00 – 11.30	Prof. Jos Jonkers, Netherlands Cancer Institute <i>PARP inhibitor resistance mechanisms</i>
11.30 – 12.00	Dr. Lenka Oplustilova, AstraZeneca, UK <i>Normal tissue toxicity</i>
12.00 – 12.20	Dr. Sven Rottenberg, University of Bern, Switzerland <i>Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in BRCA1-deficient mammary tumor cells</i>
12.20 – 12.30	Inger Brandsma, Erasmus MC, Rotterdam. The Netherlands <i>REV7 and PARP inhibitor resistance</i>
12.20 – 14.00	Lunch



FP7 Collaborative Project DDRresponse

International Symposium on “The promise of PARP inhibitors for Personalized Cancer Treatment”

Heineken Experience, Amsterdam, NL
26-28 January, 2015



Session 3: Personalized medicine and patient selection

- 14.00 – 14.30 Prof. Jan Schellens, The Netherlands Cancer Institute
PARP inhibitors in the clinic
- 14.30 – 15.00 Prof. Andrew Tutt, King's College London
Platinums and PARP inhibitors in breast cancer, trials and patient selection biomarkers
- 15.00 – 15.30 Dr. Dik van Gent, Erasmus MC, Rotterdam, the Netherlands
Ex vivo assays for breast cancer patient selection
- 15.30 – 15.45 Dr. Maaïke Vreeswijk, Leiden University Medical Centre
Ex vivo assays for ovarian cancer patient selection
- 15.45 – 16.15 tea/coffee

Session 4: Dietary interventions

- 16.15 – 16.45 Prof. Ian Hickson, University of Copenhagen
The BLM helicase: roles in DNA repair and as a target for anticancer therapy
- 16.45 – 17.15 Dr. Ron de Bruin, Erasmus MC, The Netherlands
Improving cancer treatment by dietary restriction
- 17.15 – 17.45 Prof. Jan Hoeijmakers, Erasmus MC, Rotterdam, The Netherlands
Genome (in)stability diet and longevity

Day 3, Wednesday 28 January

Time	Presenter + Title
Session 5: New synthetic lethality approaches	
9.00 – 9.30	Dr. Chris Lord, The Institute of Cancer Research, UK <i>Extending the application of the synthetic lethal principle</i>
9.30 – 10.00	Dr. Marcel Tijsterman, Leiden University Medical Centre <i>Targeting alternative end-joining: an alternative approach to kill cancer cells!?</i>
10.00 – 10.30	Prof. Steve Jackson, University of Cambridge, UK <i>Exploiting synthetic lethality opportunities by targeting deubiquitylating enzymes</i>
10.30 – 11.00	Coffee
11.00 – 11.30	Dr. Marcel van Vugt, University Medical Center Groningen <i>Cell-cycle-dependent regulation of genomic maintenance</i>
11.30 – 12.00	Prof. Jiri Bartek, Danish Cancer Society Research Center <i>Synthetic viability and lethality in response to DNA damage: Mechanisms and relevance for cancer</i>
12.00 – 12.30	Prof. Thomas Helleday, Karolinska Institutet, Sweden <i>Beyond synthetic lethality, from PARP to MTH1 inhibitors</i>
12.30 – 12.40	Closure
12.40 – 14.00	Lunch